Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2019

Open Access 01-12-2019 | Colonoscopy | Research

Examining intrafamilial communication of colorectal cancer risk status to family members and kin responses to colonoscopy: a qualitative study

Authors: Kaitlin M. McGarragle, Crystal Hare, Spring Holter, Dorian Anglin Facey, Kelly McShane, Steven Gallinger, Tae L. Hart

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2019

Login to get access

Abstract

Background

First-degree relatives (FDRs) of probands with colorectal cancer (CRC) may be at increased risk of CRC and require colonoscopy. Proband disclosure about this risk and need for colonoscopy is essential for FDRs to take appropriate action. Low colonoscopy rates are reported among FDRs and little is known about the proband disclosure process. A better understanding of the barriers surrounding colonoscopy and disclosure is needed.

Methods

CRC probands (n = 16) and FDRs (n = 9), recruited from a Canadian CRC Consortium, completed interviews to determine barriers to disclosure and colonoscopy, respectively. Interviews were analyzed using thematic analysis and participants’ motivation to disclose to FDRs or undertake colonoscopy was categorized into Stages of Change (i.e., Precontemplation, Contemplation, Preparation, Action, or Maintenance) using the transtheoretical model.

Results

25% of probands had not disclosed to any first-degree kin and were categorized in the Precontemplation or Contemplation Stage of Change. Barriers to disclosure included lack of information, negative expectations about familial reaction, assuming FDRs were aware of risk or already being screened, dysfunctional family dynamics, and cultural barriers. 75% of FDRs were categorized in the Precontemplation or Contemplation Stage of Change. Barriers included negative perceptions about colonoscopy, health-care provider related factors, practical concerns, and lack of information about CRC, risk, and colonoscopy.

Conclusions

In the absence of barriers such as cost and accessibility, this Canadian sample still reported several challenges to disclosure and colonoscopy adherence. Future research should explore interventions such as motivational interviewing to improve proband disclosure and to increase FDR adherence to colonoscopy.
Literature
1.
go back to reference Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda. Available at: https://seer.cancer.gov/csr/1975_2015/. Accessed 18 June 2019. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda. Available at: https://​seer.​cancer.​gov/​csr/​1975_​2015/​. Accessed 18 June 2019.
2.
go back to reference Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2018. Toronto: Canadian Cancer Society; 2018. Available at: cancer.Ca/Canadian-Cancer-Statistics-2018-EN Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2018. Toronto: Canadian Cancer Society; 2018. Available at: cancer.Ca/Canadian-Cancer-Statistics-2018-EN
9.
go back to reference Lowery JT, Marcus A, Kinney A, Bowen D, Finkelstein DM, Horick N, Garrett K, Haile R, Sandler R, Ahnen DJ. The family health promotion project (FHPP): design and baseline data from a randomized trial to increase colonoscopy screening in high risk families. Contemp Clin Trials. 2012;33(2):426–35. https://doi.org/10.1016/j.cct.2011.11.005 Epub 2011 Nov 12.CrossRefPubMed Lowery JT, Marcus A, Kinney A, Bowen D, Finkelstein DM, Horick N, Garrett K, Haile R, Sandler R, Ahnen DJ. The family health promotion project (FHPP): design and baseline data from a randomized trial to increase colonoscopy screening in high risk families. Contemp Clin Trials. 2012;33(2):426–35. https://​doi.​org/​10.​1016/​j.​cct.​2011.​11.​005 Epub 2011 Nov 12.CrossRefPubMed
11.
21.
go back to reference Wang HL, Christy SM, Skinner CS, Champion VL, Springston JK, Perkins SM, Tong Y, Krier C, Gebregziabher N, Rawl SM. Predictors of stage of adoption for colorectal cancer screening among african american primary care patients. Cancer Nurs. 2014;37(4):241–51.CrossRef Wang HL, Christy SM, Skinner CS, Champion VL, Springston JK, Perkins SM, Tong Y, Krier C, Gebregziabher N, Rawl SM. Predictors of stage of adoption for colorectal cancer screening among african american primary care patients. Cancer Nurs. 2014;37(4):241–51.CrossRef
26.
go back to reference Steffen LE, Boucher KM, Damron BH, Pappas LM, Walters ST, Flores KG, Boonyasiriwat W, Vernon SW, Stroup AM, Schwartz MD, Edwards SL, Kohlmann WK, Lowery JT, Wiggins CL, Hill DA, Higginbotham JC, Burt R, Simmons RG, Kinney AY. Efficacy of a telehealth intervention on colonoscopy uptake when cost is a barrier: the family CARE cluster randomized controlled trial. Cancer Epidemiol Biomark Prev. 2015;24(9):1311–8. https://doi.org/10.1158/1055-9965.EPI-15-0150.CrossRef Steffen LE, Boucher KM, Damron BH, Pappas LM, Walters ST, Flores KG, Boonyasiriwat W, Vernon SW, Stroup AM, Schwartz MD, Edwards SL, Kohlmann WK, Lowery JT, Wiggins CL, Hill DA, Higginbotham JC, Burt R, Simmons RG, Kinney AY. Efficacy of a telehealth intervention on colonoscopy uptake when cost is a barrier: the family CARE cluster randomized controlled trial. Cancer Epidemiol Biomark Prev. 2015;24(9):1311–8. https://​doi.​org/​10.​1158/​1055-9965.​EPI-15-0150.CrossRef
27.
go back to reference Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, Lindor NM, Newcomb PA, Sandler RS, Burke C, Hill DA, Ahnen DJ. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomark Prev. 2014;23(4):601–10. https://doi.org/10.1158/1055-9965.EPI-13-1085.CrossRef Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, Lindor NM, Newcomb PA, Sandler RS, Burke C, Hill DA, Ahnen DJ. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomark Prev. 2014;23(4):601–10. https://​doi.​org/​10.​1158/​1055-9965.​EPI-13-1085.CrossRef
28.
go back to reference Kinney AY, Boonyasiriwat W, Walters ST, Pappas LM, Stroup AM, Schwartz MD, Edwards SL, Rogers A, Kohlmann WK, Boucher KM, Vernon SW, Simmons RG, Lowery JT, Flores K, Wiggins CL, Hill DA, Burt RW, Williams MS, Higginbotham JC. Telehealth personalized cancer risk communication to motivate colonoscopy in relatives of patients with colorectal cancer: the family CARE randomized controlled trial. J Clin Oncol. 2014;32(7):654–62. https://doi.org/10.1200/JCO.2013.51.6765.CrossRefPubMedPubMedCentral Kinney AY, Boonyasiriwat W, Walters ST, Pappas LM, Stroup AM, Schwartz MD, Edwards SL, Rogers A, Kohlmann WK, Boucher KM, Vernon SW, Simmons RG, Lowery JT, Flores K, Wiggins CL, Hill DA, Burt RW, Williams MS, Higginbotham JC. Telehealth personalized cancer risk communication to motivate colonoscopy in relatives of patients with colorectal cancer: the family CARE randomized controlled trial. J Clin Oncol. 2014;32(7):654–62. https://​doi.​org/​10.​1200/​JCO.​2013.​51.​6765.CrossRefPubMedPubMedCentral
Metadata
Title
Examining intrafamilial communication of colorectal cancer risk status to family members and kin responses to colonoscopy: a qualitative study
Authors
Kaitlin M. McGarragle
Crystal Hare
Spring Holter
Dorian Anglin Facey
Kelly McShane
Steven Gallinger
Tae L. Hart
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2019
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-019-0114-8

Other articles of this Issue 1/2019

Hereditary Cancer in Clinical Practice 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine